Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | ERN1 | O75460 | 18/20 | 0.64 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784079 | 0.89 | PTPN1 (0.61) | LMNAMAPTERN1AKR1B1 | |
| SCHEMBL24784504 | 0.88 | ERN1 (0.64) | LMNAMAPTERN1 | |
| SCHEMBL8154869 | 0.88 | LMNA (0.69) | LMNAMAPTERN1TLR2TLR1 | |
| SCHEMBL14262144 | 0.88 | LMNA (0.69) | LMNAMAPTERN1TLR2TLR1 | |
| SCHEMBL5644612 | 0.88 | LMNA (0.69) | LMNAMAPTERN1TLR2TLR1 | |
| SCHEMBL22993856 | 0.86 | LMNA (0.68) | LMNAMAPTERN1TLR2TLR1 | |
| SCHEMBL15921273 | 0.86 | LMNA (0.68) | LMNAMAPTERN1 | |
| SCHEMBL31346730 | 0.86 | LMNA (0.68) | LMNAMAPTERN1 | |
| SCHEMBL7251427 | 0.86 | LMNA (0.59) | LMNAMAPTERN1 | |
| SCHEMBL24784689 | 0.86 | ERN1 (0.62) | LMNAMAPTERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43067-E1 | Method for producing new polynuclear poly(formylphenol) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-7875743-B2 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7750190-B2 | reacting hexamethylene tetramine in presence of acid; industrial scale; photoresists | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090182175-A1 | METHOD FOR PRODUCING NEW POLYNUCLEAR POLY(FORMYLPHENOL) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182175-A1 | METHOD FOR PRODUCING NEW POLYNUCLEAR POLY(FORMYLPHENOL) | PCBP1, FPR2, PNKP | LMNA 2090/4885MAPT 3943/4885ERN1 2895/4885 |
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | PAH, PGM2, HNMT | LMNA 1330/4885MAPT 3944/4885ERN1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.